Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXS NASDAQ:NTRP NASDAQ:PDSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/ANTRPNextTrip$2.05-1.4%$2.59$2.00▼$5.20$30.15M1.0350,614 shs30,747 shsPDSBPDS Biotechnology$0.96-5.9%$1.11$0.51▼$1.85$56.93M1.571.02 million shs1.36 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+401.70%NTRPNextTrip-3.70%-11.11%-14.05%-26.50%-39.88%PDSBPDS Biotechnology-2.86%+2.00%-23.88%+47.83%-41.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.60$0.60$0.00▼$0.80$35.79M1.7515,632 shsN/ANTRPNextTrip$2.05-1.4%$2.59$2.00▼$5.20$30.15M1.0350,614 shs30,747 shsPDSBPDS Biotechnology$0.96-5.9%$1.11$0.51▼$1.85$56.93M1.571.02 million shs1.36 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%0.00%0.00%+401.70%NTRPNextTrip-3.70%-11.11%-14.05%-26.50%-39.88%PDSBPDS Biotechnology-2.86%+2.00%-23.88%+47.83%-41.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/ANTRPNextTrip 2.00Hold$7.50265.85% UpsidePDSBPDS Biotechnology 2.33Hold$9.00837.50% UpsideCurrent Analyst Ratings BreakdownLatest ADXS, NTRP, and PDSB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026NTRPNextTrip Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $7.506/4/2026NTRPNextTrip Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026PDSBPDS Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/15/2026PDSBPDS Biotechnology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.003/27/2026NTRPNextTrip Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/17/2026NTRPNextTrip Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M11.05N/AN/A($2.06) per share-0.29NTRPNextTrip$3.72M7.99N/AN/A$0.42 per share4.88PDSBPDS BiotechnologyN/AN/AN/AN/A$0.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$5.02N/AN/AN/AN/AN/AN/AN/ANTRPNextTrip-$15.91M-$1.87N/AN/AN/A-428.20%-249.26%-117.47%7/14/2026 (Estimated)PDSBPDS Biotechnology-$34.50M-$0.67N/AN/AN/AN/A-346.02%-102.36%8/12/2026 (Estimated)Latest ADXS, NTRP, and PDSB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/14/2026N/ANTRPNextTrip-$0.22N/AN/AN/A$1.30 millionN/A5/13/2026Q1 2026PDSBPDS Biotechnology-$0.15-$0.13+$0.02-$0.13N/AN/A3/30/2026Q4 2025PDSBPDS Biotechnology-$0.20-$0.14+$0.06-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/ANTRPNextTripN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/ANTRPNextTrip0.020.810.81PDSBPDS Biotechnology2.732.262.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%NTRPNextTrip3.81%PDSBPDS Biotechnology26.84%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%NTRPNextTrip44.50%PDSBPDS Biotechnology9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2059.31 million42.36 millionNot OptionableNTRPNextTrip1214.49 million8.04 millionNo DataPDSBPDS Biotechnology2055.82 million50.68 millionOptionableADXS, NTRP, and PDSB HeadlinesRecent News About These CompaniesPDS Biotechnology Sets 2026 Annual Stockholders Meeting DateJune 15 at 8:50 AM | tipranks.comHere's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom FisherJune 10, 2026 | zacks.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2026 Earnings Call TranscriptMay 15, 2026 | insidermonkey.comPDS Biotechnology Q1 2026 Earnings Call: Complete TranscriptMay 15, 2026 | finance.yahoo.comPDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...May 15, 2026 | finance.yahoo.comPDS Biotechnology Corporation Schedules Investor Webcast for Business and Clinical UpdateMay 13, 2026 | quiverquant.comQPDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate UpdateMay 13, 2026 | markets.businessinsider.comPDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate UpdateMay 13, 2026 | globenewswire.comPDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial ResultsMay 6, 2026 | globenewswire.comPDS Biotechnology Corp.April 22, 2026 | barrons.comB. Riley Securities Sticks to Their Buy Rating for PDS Biotechnology (PDSB)April 17, 2026 | theglobeandmail.comPDSB stock hits 37-week high — here’s the latest on its therapy to treat metastatic colorectal cancerApril 15, 2026 | msn.comPDS Biotechnology Announces Promising Phase 2 Trial Results of PDS01ADC for Treatment of Colorectal Liver MetastasesApril 15, 2026 | quiverquant.comQPDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) TrialApril 15, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Eli Lilly & Co (LLY) and Praxis Precision Medicines (PRAX)April 7, 2026 | theglobeandmail.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 earnings call transcriptApril 1, 2026 | msn.comPDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Highlights: Financial Discipline Amid ...March 31, 2026 | finance.yahoo.comPDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call TranscriptMarch 30, 2026 | seekingalpha.comPDS Biotechnology: Q4 Earnings SnapshotMarch 30, 2026 | finance.yahoo.comPDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical AdvancementMarch 30, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADXS, NTRP, and PDSB Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.60 0.00 (0.00%) As of 06/15/2026Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.NextTrip NASDAQ:NTRP$2.05 -0.03 (-1.44%) Closing price 04:00 PM EasternExtended Trading$2.13 +0.08 (+3.85%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NextTrip, Inc., through its subsidiaries, engages in the provision of travel technology solutions in the United States. The company offers NXT2.0, a booking engine technology platform, which provides travel distributors access to an inventory. It is also involved in the provision of online leisure travel agency services for booking hotels, flights, and curated vacations. The company was formerly known as Sigma Additive Solutions, Inc. and changed its name to NextTrip, Inc. in March 2024. NextTrip, Inc. is based in Sunrise, Florida.PDS Biotechnology NASDAQ:PDSB$0.96 -0.06 (-5.88%) Closing price 04:00 PM EasternExtended Trading$0.95 -0.01 (-1.15%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
